Crescent Biopharma, Inc. (CBIO) vs 908 Devices Inc. (MASS)
A side-by-side comparison of Crescent Biopharma, Inc. and 908 Devices Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CBIO
Crescent Biopharma, Inc.
$14.30HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT
MASS
908 Devices Inc.
$12.48HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT
Total return — CBIO vs MASS
growth of $100 · dividends reinvested · last 6yCBIO -86.6% (-28.5%/yr)MASS -73.9% (-20.0%/yr)MASS compounded faster over this window
CBIO MASS
CBIO vs MASS: by the numbers
- •CBIO is the larger company ($531M vs $512M market cap).
- •Both run net losses; MASS's is the smaller (-56.68% vs -1371.51% net margin).
- •CBIO grew revenue faster over the past five years (39.89% vs 18.92% CAGR).
Metrics side by side
Valuation
| Metric | CBIO | MASS |
|---|---|---|
| P/S ratio | 44.70 | 8.42 |
| P/B ratio | 3.34 | 4.04 |
| FCF yield | N/A | 0.09% |
Profitability
| Metric | CBIO | MASS |
|---|---|---|
| Gross margin | 100.00% | 49.79% |
| Operating margin | -1407.52% | -46.01% |
| Net margin | -1371.51% | -56.68% |
| ROE | -99.83% | -27.20% |
| ROIC | -102.59% | -18.90% |
Growth (annualized)
| Metric | CBIO | MASS |
|---|---|---|
| Revenue CAGR (5Y) | 39.89% | 18.92% |
| Total return CAGR (5Y) | -24.40% | -17.66% |
Frequently asked
- Which has grown faster, CBIO or MASS?
- Over the past five years, CBIO grew revenue faster — CBIO at a 39.89% CAGR versus MASS at 18.92%.
- How have CBIO and MASS total returns compared?
- Over the past 5 years, CBIO delivered -24.40% and MASS delivered -17.66% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Crescent Biopharma ROE908 Devices ROECrescent Biopharma operating margin908 Devices operating marginCrescent Biopharma revenue growth908 Devices revenue growthCrescent Biopharma free cash flow908 Devices free cash flow
Crescent Biopharma & 908 Devices appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.